<DOC>
	<DOCNO>NCT02525484</DOCNO>
	<brief_summary>This Phase I , open-label , randomize , four-treatment period , four-sequence , single-dose , crossover pharmacokinetic study determine bioequivalence pirfenidone administration tablet capsule dosage form feed fasted condition .</brief_summary>
	<brief_title>A Bioequivalence Study Comparing Pirfenidone Tablet Capsule Dosage Forms Healthy Adult Participants</brief_title>
	<detailed_description />
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>Participants 18 55 year age , inclusive , time screen Participants body mass index 18.530.0 kilogram per square meter ( kg/m^2 ) , inclusive Participants reproductive potential must willing use reliable contraceptive method Participants significant medical history unstable hepatic , pulmonary , metabolic , neurologic , cardiovascular , gastrointestinal , hematologic , psychiatric system , opinion investigator may alter absorption , metabolism , elimination study drug Participants calculate creatinine clearance rate le ( &lt; ) 30 milliliter per minute ( mL/min ) ( calculate use CockcroftGault equation ) screen Participants use , intent use , medication , include prescription , overthecounter , herbal preparation , vitamin/mineral supplementation study medication 14 day screen followup telephone call ( except contraception purpose ) Participants received fluvoxamine therapy within 28 day screen Participants receive medication know chronically alter drug absorption , metabolism , elimination process within 28 day screen , participant take drug know affect liver function , opinion Sponsor investigator Participants take investigative drug and/or device another clinical study within 28 day within investigational drug 5 halflives , whichever longer , screen Participants previously dose pirfenidone clinical study Participants hypersensitivity idiosyncratic reaction pirfenidone constituent pirfenidone Participants elevation liver test result ( alanine aminotransferase [ ALT ] , aspartate aminotransferase [ AST ] , gammaglutamyl transferase [ GGT ] , direct bilirubin , alkaline phosphatase upper limit normal ) Participants follow hemoglobin level screen : male &lt; 13.5 gram per deciliter ( g/dL ) , females &lt; 11.5 g/dL Females positive serum pregnancy test breastfeeding Participants seropositive hepatitis B surface antigen , hepatitis C virus antibody , human immunodeficiency ( HIV ) antibodies screen Participants clinically significant abnormal electrocardiogram ( ECG ) screen Fridericia correct QT interval ( QTcF ) great ( &gt; ) 500 millisecond ( m ) screen Participants plasma donation within 28 day screen donation blood blood product significant blood loss within 56 day screen Participants poor venous access Participants use cigarette ( include vapor cigarette ) , cigar , nicotinecontaining product within 3 month screen plan use completion followup telephone call Participants history alcoholism drug abuse , per discretion investigator , within 2 year screen positive qualitative drug screen drug abuse screen Day 1 Participants withhold alcoholic beverages/alcoholcontaining product caffeinated beverages/caffeine xanthinecontaining product least 72 hour first study dose administration plan consume study positive qualitative drug screen alcohol screen Day 1 Participants abnormal diet ( determined investigator ) within 28 day first study dose administration Participants withhold consume cruciferous vegetable ( broccoli , kale , Brussels sprout ) , grapefruit grapefruit juice , chargrilled meat 48 hour dose plan consume study Participants refrain strenuous exercise 48 hour first study dose administration completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>